Mark Markowski
Hematology & Oncology · Baltimore, MDNPI 1689809188
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Medivation LLC. at 41.1% of the total. Reporting peaked in 2023 at $800 and has fallen 78.3% since, to $174 in 2024. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 10 payments — averaging $171.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medivation LLC.$704
- Sanofi$688
- Exelixis Inc.$174
- AVEO Pharmaceuticals, Inc.$96
- EMD Serono, Inc.$51
Across 274 payments — averaging $21,450 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.5M
- Pfizer$1.8M
- Medivation LLC.$988K
- Exelixis Inc.$471K
- GSK$71K
- Clovis Oncology, Inc.$70K
- plus $29K from 1 others
What the payments were for
- Consulting fees$70441%
- Travel & lodging$43425%
- Food & beverage$42825%
- Education$1479%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medivation LLC. | 1 | $704 |
| Sanofi | 6 | $688 |
| Exelixis Inc. | 1 | $174 |
| AVEO Pharmaceuticals, Inc. | 1 | $96 |
| EMD Serono, Inc. | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$704
- NO PRODUCT DISCUSSED$573
- Cabometyx$174
How this compares
$1,713 in reported general payments places this provider in the 45th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 40 | $532,558 |
| RevlimidLenalidomide | 13 | $220,827 |
| XtandiEnzalutamide | 17 | $219,348 |
| ErleadaApalutamide | 12 | $172,542 |
| ZytigaAbiraterone Acetate | 11 | $119,854 |
| Abiraterone Acetate | 82 | $91,227 |
| XareltoRivaroxaban | 16 | $12,978 |
| Prednisone | 107 | $465 |
| Dexamethasone | 12 | $325 |
| Bicalutamide | 21 | $302 |
| Tamsulosin Hcl | 26 | $281 |
| Prochlorperazine Maleate | 12 | $142 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Baltimore
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Huzefa BahrainBaltimore$102K
- Tania JainBaltimore$95K
- Josephine FelicianoBaltimore$72K
- Abhijeet KumarBaltimore$66K
- Michael AuerbachBaltimore$64K
- Suman RaoBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.